Katsunuma 1993.
Methods | Setting: Japan, hospital outpatient clinic Length of intervention period: 8 weeks Randomisation: yes, method not stated Allocation concealment: unclear Design: crossover, no washout Masking: single blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score: 3 | |
Participants | 22 children/adults: 13 M 9 F Age range: 9‐24 years Inclusion criteria: Allergic asthma (not further defined) Exclusion criteria: Use of oral steroids currently or in previous 3 months | |
Interventions | BDP: either 150 mcg 2xdaily or 100 mcg 3xdaily (300 mcg/d) Placebo: 2 or 3 x daily Delivery device: MDI |
|
Outcomes | FEV1 (% predicted) Methacholine BHR (Dmin) | |
Notes | No reply from author to clarify details of randomisation method. A significant carryover effect was calculated for FEV1 (% predicted) when individual patient data was estimated from the graphical plot for this outcome. It was not possible to assess carryover effect for methacholine challenge Dmin (data presented in graph form using logarithmic scale). The combined period data for this outcome was not therefore included in the meta‐analysis. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |